SEGMENT REPORTING - Additional disaggregated significant segment expenses (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| SEGMENT REPORTING | ||||||
| Segment Loss | $ 7,020 | $ 6,050 | $ 6,334 | $ 5,332 | $ 13,070 | $ 11,666 |
| Clinical development | ||||||
| SEGMENT REPORTING | ||||||
| Other Segment Items | (176) | (248) | (386) | (471) | ||
| Segment Loss | $ 7,020 | $ 6,334 | $ 13,070 | $ 11,666 | ||
| Description of other segment items | Other Segment Items included in net loss include finance income. | Other Segment Items included in net loss include finance income. | Other Segment Items included in net loss include finance income. | Other Segment Items included in net loss include finance income. | ||
| Clinical development | Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense | ||||||
| SEGMENT REPORTING | ||||||
| Employee Expenses | $ 568 | $ 472 | $ 1,169 | $ 974 | ||
| Professional Fees | 1,537 | 2,045 | 2,694 | 3,002 | ||
| Insurance and other | 408 | 465 | 804 | 894 | ||
| Clinical development | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | ||||||
| SEGMENT REPORTING | ||||||
| Employee Expenses | 1,961 | 1,639 | 4,026 | 3,356 | ||
| Clinical Trial Expenses | 1,955 | 1,605 | 3,167 | 2,641 | ||
| Manufacturing | 766 | $ 356 | 1,595 | 832 | ||
| License Fees | $ 1 | $ 1 | $ 438 | |||
| X | ||||||||||
- Definition Amount of expense for clinical trial expenses. No definition available.
|
| X | ||||||||||
- Definition The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production, and others. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate costs incurred in the production of goods for sale. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Description of composition of other segment item not separately disclosed. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of tax expense, excluding income, excise, production and property taxes, and licenses and fees not related to production. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|